RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
HLS Therapeutics Stock

HLS Therapeutics ROE 2024

HLS Therapeutics ROE

-0.28

Ticker

HLS.TO

ISIN

CA40390B1094

WKN

A2JGH0

In 2024, HLS Therapeutics's return on equity (ROE) was -0.28, a 49.62% increase from the -0.19 ROE in the previous year.

HLS Therapeutics Aktienanalyse

What does HLS Therapeutics do?

HLS Therapeutics Inc. is a Canadian pharmaceutical company focused on the development and distribution of medical products in the North American market. It was founded in 2018 and is headquartered in Toronto, Canada. HLS Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding HLS Therapeutics's Return on Equity (ROE)

HLS Therapeutics's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing HLS Therapeutics's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

HLS Therapeutics's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in HLS Therapeutics’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about HLS Therapeutics stock

What is the ROE (Return on Equity) of HLS Therapeutics this year?

The ROE of HLS Therapeutics this year is -0.28 undefined.

How has the Return on Equity (ROE) of HLS Therapeutics developed compared to the previous year?

The ROE of HLS Therapeutics has increased by 49.62% increased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of HLS Therapeutics?

A high ROE indicates that HLS Therapeutics generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of HLS Therapeutics?

A low ROE can indicate that HLS Therapeutics is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of HLS Therapeutics affect the company?

A change in ROE (Return on Equity) of HLS Therapeutics can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of HLS Therapeutics?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of HLS Therapeutics?

Some factors that can influence HLS Therapeutics's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does HLS Therapeutics pay?

Over the past 12 months, HLS Therapeutics paid a dividend of 0.2 USD . This corresponds to a dividend yield of about 7.9 %. For the coming 12 months, HLS Therapeutics is expected to pay a dividend of 0.18 USD.

What is the dividend yield of HLS Therapeutics?

The current dividend yield of HLS Therapeutics is 7.9 %.

When does HLS Therapeutics pay dividends?

HLS Therapeutics pays a quarterly dividend. This is distributed in the months of August, November, February, May.

How secure is the dividend of HLS Therapeutics?

HLS Therapeutics paid dividends every year for the past 0 years.

What is the dividend of HLS Therapeutics?

For the upcoming 12 months, dividends amounting to 0.18 USD are expected. This corresponds to a dividend yield of 7.28 %.

In which sector is HLS Therapeutics located?

HLS Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von HLS Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of HLS Therapeutics from 6/15/2023 amounting to 0.05 USD, you needed to have the stock in your portfolio before the ex-date on 4/27/2023.

When did HLS Therapeutics pay the last dividend?

The last dividend was paid out on 6/15/2023.

What was the dividend of HLS Therapeutics in the year 2023?

In the year 2023, HLS Therapeutics distributed 0.2 USD as dividends.

In which currency does HLS Therapeutics pay out the dividend?

The dividends of HLS Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von HLS Therapeutics

Our stock analysis for HLS Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of HLS Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.